Resmirom 60mg Tab 30s

What it is used for: Liver Disorder.

Indications as listed by the manufacturer: Resmetirom is indicated in conjunction with diet and exercise for the treatment of adults with noncirrhotic nonalcoholic steatohepatitis (NASH) with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis) .

How it works: Resmetirom is a partial agonist of the thyroid hormone receptor-beta (THR-β). Resmetirom produced 83.8% of the maximum response compared to triiodothyronine (T3), with an EC50 of 0.21 µM in an in vitro functional assay for THR-β activation. The same functional assay for thyroid hormone receptor-alpha (THR-α) agonism showed 48.6% efficacy for Resmetirom relative to T3, with an EC50 of 3.74 µM. THR-β is the major form of THR in the liver, and stimulation of THR-β in the liver reduces intrahepatic triglycerides, whereas actions of thyroid hormone outside the liver, including in heart and bone, are largely mediated through THR-α.

Active ingredient: Resmetirom.

Reported side effects: Following adverse reactions have been reported with the use of Resmetirom : Hepatotoxicity, gallbladder-related adverse reactions , urticaria, rash, diarrhea, nausea, pruritus, vomiting, constipation, abdominal pain and dizziness.

Known drug interactions: Strong or Moderate CYP2C8 Inhibitors : Resmetirom is a CYP2C8 substrate. Concomitant use with a strong or moderate CYP2C8 inhibitor can increase Resmetirom Cmax and AUC, which may increase the risk of Resmetirom adverse reactions. Concomitant use of Resmetirom with strong CYP2C8 inhibitors (e.g., gemfibrozil) is not recommended. Reduce Resmetirom dosage if used concomitantly with a moderate CYP2C8 inhibitor (e.g., clopidogrel). Organic Anion-Transporting Polypeptides (OATP) 1B1 and OATP1B3 Inhibitors : Resmetirom is an OATP1B1 and OATP1B3 substrate. Concomitant use with OATP1B1 and OATP1B3 inhibitors may increase Resmetirom Cmax and AUC, which may increase the risk of Resmetirom adverse reactions. Concomitant use of Resmetirom with OATP1B1 or OATP1B3 inhibitors (e.g., cyclosporine) is not recommended.

The recommended dosage of RESMIROM (Resmetirom) is based on actual body weight. For patients weighing : <100kg, the recommended dosage is 80mg orally once daily . ≥100kg, the recommended dosage is 100mg orally once daily .

Active ingredient: Resmetirom. Labelled strength: 60mg.

Store this medicine at room temperature, away from direct light and heat.

Manufactured by Resmirom Healthcare (Pvt) Ltd.. Country of origin: United Kingdom.